The odyssey of marine pharmaceuticals: a current pipeline perspective.

By Alejandro M Mayer, K. Glaser, C. Cuevas, R. Jacobs, W. Kem, R. Little, J. Mcintosh, D. Newman, B. Potts, D. Shuster. TIPS - Trends in Pharmacological Sciences, 2010

632 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/9aa047c3d18c8fd10dfa8637dfc2f0e9c8509e64

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Public Health, Environmental and Occupational Health

1. J. Anthony
2. David C. Swinney

Citations in the corpus

• How were new medicines discovered? (2011, background): “Finally, as has often been noted in reviews of the role of natural products in drug discover”
• A Historical Overview of Natural Products in Drug Discovery (2012, methodology): “In October 2007, Trabectedin (35) (also known as Ecteinascidin 743 or ET-743) (Yondelis, PharmaMar) became the first marine anticancer drug to be approved in the European Union [78].”
• Lessons from the past and charting the future of marine natural products drug discovery and chemical biology (2012, background): “Chemistry & Biology 19, January 27, 201 vated once a screening campaign is completed (Mayr and Bojanic, 2009).”
• An Overview on Marine Sponge-Symbiotic Bacteria as Unexhausted Sources for Natural Product Discovery (2017, background): “The molecular structure of sponge-derived compounds (a) Ara-C (cytarabine) an anticancer agent; (b) Ara-A (vidarabine) an antiviral agent [119]; (c) theopalauamide an antifungal agent [110]; and (d) cibrostatin 3 an antibacterial agent [120].”